Phio Pharmaceuticals Corp. (Nasdaq: PHIO) — Life Sciences Virtual Investor Forum 2026

The ‪@b2idigital‬ team is pleased to highlight that ‪@PhioPharmaceuticalsCorp.‬ (Nasdaq: PHIO) presented at the Life Sciences Virtual Investor Forum at 3:00 PM ET on Thursday, June 25, 2026. The event was co-hosted by Virtual Investor Conferences and ‪@ZacksSmallCap‬ Research. The Life Sciences Virtual Investor Forum is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/vic-june-25th-... Phio Pharmaceuticals is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/phio-pharmaceu... View all presentations from the event: https://www.virtualinvestorconference... Robert Bitterman, President and CEO, presents for Phio Pharmaceuticals. He has chaired the company's board since 2012 and has led as President and CEO since 2023, with prior chief executive roles at Cutanea Life Sciences and Isolagen. Phio Pharmaceuticals is developing therapeutics using INTASYL, a chemically modified siRNA technology designed to silence specific genes that hinder the immune system's ability to fight cancer, with a focus on immuno-oncology. Unlike many siRNA approaches that rely on complex delivery systems such as lipid nanoparticles, INTASYL compounds are engineered to self-deliver into cells without additional formulations, simplifying administration and potentially reducing toxicity. Learn more at https://phiopharma.com/investors/. Virtual Investor Conferences is an ‪@OTCMarketsGroup‬ Inc. property. Learn more at www.virtualinvestorconferences.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. B2i Digital is the Official Marketing Partner of Virtual Investor Conferences. Content is informational only and is not investment advice. B2i Digital is not a broker-dealer or investment adviser.